Sacituzumab tirumotecan is an emerging antibody–drug conjugate (ADC) that is attracting growing attention in oncology for its potential to expand the therapeutic landscape for patients with solid tumors, particularly lung and gastrointestinal cancers. As precision oncology increasingly relies on targeted delivery of potent cytotoxic payloads, ADCs have become one of the most dynamic areas of anticancer drug development. Sacituzumab tirumotecan represents a next-generation approach in this class, combining targeted antibody specificity with a highly potent topoisomerase I inhibitor payload designed to selectively eliminate tumor cells while limiting systemic toxicity.
The rapid development of sacituzumab tirumotecan reflects the broader shift toward targeted cytotoxic therapy in oncology, where…